Drug intelligence / Profile preview

RLD2001-2

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RLD2001-2 is an investigational small molecule drug being developed by Hanmi Pharmaceutical Company Limited for the treatment of essential hypertension. The precise mechanism of action for RLD2001-2 has not been disclosed and remains unknown. The drug is administered orally and, as of now, has not received regulatory approval in any country nor does it have any known adverse events reported. Clinical development is ongoing, with no evidence yet of approval or marketing authorization in any region[1].

Beyond the preview

Go deeper on RLD2001-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD2001-2.

Explore the full profile